| 18th week of 2016 patent applcation highlights part 9 |
| Patent application number | Title | Published |
|---|
| 20160120899 | Drug Combinations and Uses in Treating a Coughing Condition - The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions. | 2016-05-05 |
| 20160120900 | COMPOSITION FOR THE ORAL ADMINISTRATION OF MAGNESIUM, IN ASSOCIATION WITH A COMPOSITION FOR TREATING TYPE 2 DIABETES OR THE COMPLICATIONS THEREOF - The invention relates to a specific composition for oral administration of magnesium, for using in the treatment of type 2 diabetes or the complications thereof, in association with a composition for treating type 2 diabetes or the complications thereof. | 2016-05-05 |
| 20160120901 | HEMOSTATIC COMPOSITIONS, DEVICES, AND METHODS - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery. | 2016-05-05 |
| 20160120902 | MONO (IRON HYDROXYPYRONE) AND COMBINATION (IRON HYDROXYPYRONE AND GI INFLAMMATION INHIBITING AGENTS) COMPOSITIONS FOR ANAEMIA OR H. PYLORI INFECTIONS - There is provided a composition or kit of parts comprising: one or more compounds capable of treating and/or preventing an inflammatory disease of the gastrointestinal tract: and an iron hydroxypyrone, for increasing the level of iron in a patient's bloodstream and/or treating and/or preventing anaemia such as iron deficiency anaemia. A composition comprising iron hydroxypyrone is also provided for administration to a subject: having or at risk of having achlorhydria; wherein the gastric pH of the subject is equal to or greater than about 4; or wherein the subject has an inflammatory disease of the gastrointestinal tract. | 2016-05-05 |
| 20160120903 | Topical Relief Cream Formulation for Allergic Reactions to Poison Ivy, Poison Oak, Poison Sumac, Minor Skin Irritations and Insect Bites - A topical relief cream formulation for allergic reactions to poison ivy, poison oak, poison sumac, minor skin irritations and insect bites through chemical means. The relief cream formulation includes a quantity of zinc acetate, a quantity of zinc oxide, a quantity of pramoxine, a quantity of camphor, and a quantity of menthol suspended in a topical lotion base. The aforementioned compounds provide several medicinal properties from analgesic, anesthetic, antiseptic, and astringent categories when applied locally to an area of skin affected by the oils found in poison ivy, poison oak, and poison sumac, as well as, minor skin irritations and insect bites. | 2016-05-05 |
| 20160120904 | Reactive Oxidative Species Generating Materials and Methods of Use - Materials capable of delivering stabilized free radicals to targeted treatment sites. The materials comprise semi-crystalline, hydrolytically degradable polymers that are subjected to ionizing radiation to create stabilized free radicals therein. Upon exposure to oxygen containing aqueous media, the materials generate reactive oxidative species which are useful in biological processes. | 2016-05-05 |
| 20160120905 | METHODS FOR ENGINEERING ALLOGENEIC AND HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY - The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections. | 2016-05-05 |
| 20160120906 | METHODS FOR ENGINEERING HIGHLY ACTIVE T CELL FOR IMMUNOTHERAPHY - The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections. | 2016-05-05 |
| 20160120907 | T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS - The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same. | 2016-05-05 |
| 20160120908 | APPLICATION OF MESENCHYMAL STEM CELLS IN PROPHYLAXIS OR TREATMENT OF STRESS RESPONSE-INDUCED WEAKENED IMMUNITY - The present invention discloses the application of mesenchymal stem cells in the prophylaxis or treatment of stress response-induced weakened immunity. More particularly, the present invention provides the use of mesenchymal stem cells in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced lymphopenia; and/or the use thereof in preparing a pharmaceutical composition for the prophylaxis or treatment of stress response-induced weakened immunity; and/or the use thereof in preparing a pharmaceutical composition for the promotion of interleukin 4 (IL-4) expression and/or enhanced or strengthened activity. The present invention has found that mesenchymal stem cells can, by means of regulating IL-4 and down-stream related signaling pathways, protect against hormonal disorder-induced lymphopenia, thus having the function of activating immune response. | 2016-05-05 |
| 20160120909 | Compositions And Methods For The Treatment Of Tinnitus - In one embodiment, the present invention relates to a method for treating tinnitus in a subject including administering to the subject a composition including a stromal vascular fraction from adipose tissue. In another embodiment, the present invention relates to a method for treating tinnitus in a subject including administering to the subject a composition including a bone marrow cellular fraction. In another embodiment, the present invention relates to a method of treating tinnitus in a subject including administering to the subject a composition including adult stem cells. | 2016-05-05 |
| 20160120910 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF - The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stem cells. | 2016-05-05 |
| 20160120911 | TRANSPLANTATION OF CELLS INTO THE NASAL CAVITY AND THE SUBARACHNOID CRANIAL SPACE - A method of transplanting cells into a subject is disclosed. The method comprises transplanting the cells into the paranasal sinus of the subject or the subarachnoid cavity situated between the frontal bone of skull and the olfactory bulb of the subject. Devices for paranasal sinus transplantation and subarachnoid cavity transplantation are also disclosed. | 2016-05-05 |
| 20160120912 | COMPOSITIONS AND METHOD FOR PROMOTING NERVE GROWTH AND REGENERATION - The invention relates generally to the fields of biology and health sciences. More particularly, the invention relates to compositions and methods for modulating cellular physiology and pathological processing using a combination of compounds that can be found in amniotic membrane tissue and umbilical cord tissue preparations. | 2016-05-05 |
| 20160120913 | Treating renal cancer with a whole, leech saliva extract - Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2016-05-05 |
| 20160120914 | TREATING A LYMPHOMA WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a melanoma. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2016-05-05 |
| 20160120915 | METHODS FOR MANIPULATING IMMUNE RESPONSES BY ALTERING MICROBIOTA - The present invention relates to characterizing changes in mammalian microbiota associated with antibiotic treatments and various immunological conditions and related therapeutic methods. Therapeutic methods of the invention involve the use of probiotics, prebiotics, synbiotics, and antibiotics. | 2016-05-05 |
| 20160120916 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS - Some embodiments include probiotics for use in treatment of one or more autism spectrum disorder (ASD) or epilepsy in a subject in need thereof. The probiotics can comprise | 2016-05-05 |
| 20160120917 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS - Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The subject in need thereof can have a gut microbiota signature characteristic of an adult. The bacterial species can include | 2016-05-05 |
| 20160120918 | COMPOSITIONS AND METHODS FOR TREATMENT OF MICROBIAL INFECTIONS - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 2016-05-05 |
| 20160120919 | PREVENTIVE OR THERAPEUTIC AGENT FOR RUMINANT ANIMAL MASTITIS - The present invention relates to a substance or method for preventing or treating mastitis in ruminant animals, particularly in dairy cows. Specifically provided are: a preventive or therapeutic agent, a feed additive, a feed, and a pharmaceutical composition for ruminant animal mastitis, characterized by comprising, as an active ingredient, a | 2016-05-05 |
| 20160120920 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS - Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include | 2016-05-05 |
| 20160120921 | COMPOSITIONS COMPRISING DEHYDRATED MICRO-ORGANISMS, METHOD OF PREPARATION THEREOF, AND USES THEREOF - The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 μm. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products. | 2016-05-05 |
| 20160120922 | A Dosing Regime and Formulations for Type B Adenovirus - The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×10 | 2016-05-05 |
| 20160120923 | EXTRACT OF CYNARA SSP. AND USES THEREOF - The present invention relates to an extract of | 2016-05-05 |
| 20160120924 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING SIGNS OR SYMPTOMS OF EYE DISEASE - Compositions and methods for the treatment and prevention of at least one of a sign and a symptom associated with an eye disease are disclosed. Preferred compositions could comprise a liquid formulation including | 2016-05-05 |
| 20160120925 | DRUG CONTAINING THYME AND PRIMROSE OR THYME AND IVY AS A PDE-4 INHIBITOR - The invention relates to an extract from thyme ( | 2016-05-05 |
| 20160120926 | MELALEUCA QUINQUENERVIA EXTRACTS AND USES OF THE SAME | 2016-05-05 |
| 20160120927 | PHARMACEUTICAL COMPOSITIONS FOR TREATING THERMAL INJURIES AND WOUNDS COMBINED WITH BONE INJURIES - The present invention relates to a pharmaceutical composition for treating thermal injuries and wounds combined with bone injuries. More specifically, the present invention relates to a pharmaceutical composition for treating thermal injuries and wounds combined with bone injuries characterized in consisting of 4%-12% beeswax and 88%-96% sesame oil extract containing such raw materials as | 2016-05-05 |
| 20160120928 | NASAL SPRAY - The invention relates to novel formulations for treating rhinitis, sinusitis, and allergies with a fast onset of action, long duration (about once or twice daily), with no or minimal irritation, and without rebound congestion. | 2016-05-05 |
| 20160120929 | EXTERNAL COMPOSITION FOR SKIN CONTAINING AN ENZYME-TREATED SAPONIN FRACTION DERIVED FROM THE ROOT OF CAMELLIA SINENSIS - The present invention relates to a composition comprising the saponin fraction derived from the root of | 2016-05-05 |
| 20160120930 | COMPOSITION FOR ENHANCING SEMEN QUALITY IN A MALE SUBJECT - The present invention relates to a composition comprising a dry preparation of | 2016-05-05 |
| 20160120931 | METHODS AND COMPOSITIONS FOR REGULATING SRCA2A EXPRESSION LEVELS IN MYOCARDIAL INFARCTION - The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction. | 2016-05-05 |
| 20160120932 | TRANSPLANT SITE-FORMING AGENT, TRANSPLANT SITE-FORMING DEVICE, ANGIOGENIC AGENT AND ANGIOGENIC DEVICE - A method of forming a transplant site, the method comprising a process of contacting SEK-1005 (Ser,3-hydroxy-N-[2-hydroxy-1-oxo-2-tetrahydro-2-hydroxy-6-methyl-5-(2-methylpropyl)-2H-pyran-2-yl-propyl]-Leu-Pip(hexahydro-3-pyridazinecarbonyl)-N-hydroxy-Ala-N-methyl-Phe-Pip-rho-lactone) with a body tissue. | 2016-05-05 |
| 20160120933 | INHIBITORS OF MITOCHONDRIAL FISSION AND METHODS OF USE THEREOF - The present disclosure provides peptides and constructs that inhibit mitochondrial fission, and compositions comprising the peptides or constructs. The present disclosure provides methods of reducing abnormal mitochondrial fission in a cell. Also provided are methods for designing and validating mitochondrial fission inhibitor constructs and peptides, including but not limited to, evaluating the effects of the constructs and peptides on Drp1 GTPase activity, binding of Drp1 to Fis1, reduction of mitochondrial damage, reduction in cell death, inhibition of mitochondrial fragmentation in a cell under pathological conditions, and reduced loss of neurites in primary dopaminergic neurons in a Parkinsonism cell culture. | 2016-05-05 |
| 20160120934 | LUNG INJURY REPAIR COMPOSITIONS AND METHODS - The present invention provides a pharmaceutical composition comprising Protein Kinase C Zeta (PKC-ζ) inhibitor and therapeutic methods for preventing or treating a pathological condition or symptom or for inducing proliferation of lung progenitor cells in a mammal by administering the PKC-ζ inhibitor. | 2016-05-05 |
| 20160120935 | Sustanined Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers - The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs). | 2016-05-05 |
| 20160120936 | METHODS OF PREVENTING SURGICAL SITE INFECTIONS - Methods for preventing a tissue infection associated with the site of a tissue disruption, such as a surgical incision. The methods include contacting tissue at the site with a composition comprising ε-polylysine in a physiologically-acceptable carrier, such as an isotonic solution, powder or hemostatic material containing ε-polylysine. Also provided are kits for preparing antibacterial ε-polylysine compositions. | 2016-05-05 |
| 20160120937 | Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans - Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer. | 2016-05-05 |
| 20160120938 | P2X7 RECEPTOR AGONIST FOR USE IN PREVENTING OR TREATING KIDNEY INJURY - The present invention relates to the treatment or prevention of kidney injury and in particular acute kidney injury, such as acute kidney injury associated with cirrhosis. The invention relates to the treatment or prevention of such injury by administration of an agonist of the P2X7 receptor. | 2016-05-05 |
| 20160120939 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS - In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density. | 2016-05-05 |
| 20160120940 | METHODS AND USES OF SLIT FOR TREATING FIBROSIS - The present disclosure provides methods and uses of Slit protein and nucleic acid for inhibiting fibrosis and fibrotic-related disorders, for example, of the kidney, lung, heart, liver, or a wound. The Slit protein can be, for example, Slit2 or Slit2-N, or a Slit variant that can bind the Robo receptor and induce signalling. Also provided are pharmaceutical compositions comprising the Slit protein or nucleic acid and an additional anti-fibrotic agent. | 2016-05-05 |
| 20160120941 | METHODS OF USING IL-1 ANTAGONISTS TO TREAT ALZHEIMER'S DISEASE - The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the disease, or condition is treated, inhibited, or ameliorated, or wherein the onset or progression of the disease, or at least one symptom of the disease, is delayed. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult suffering from Alzheimer's Disease or cerebral amyloid angiopathy. | 2016-05-05 |
| 20160120942 | STABLE NEURAL STEM CELLS COMPRISING AN EXOGENOUS POLYNUCLEOTIDE CODING FOR A GROWTH FACTOR AND METHODS OF USE THEREOF - The present disclosure provides a human neural stem cell comprising an exogenous polynucleotide coding for a growth factor such as IGF-1. Also disclosed are methods of using the human neural stem cells for the treatment of neurodegenerative diseases or disorders including, for example, ALS. | 2016-05-05 |
| 20160120943 | ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF AND METHOD OF ADMINISTERING - The present invention provides a unit dose comprising 0.2 μg/kg to 36 μg/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof. | 2016-05-05 |
| 20160120944 | SYSTEMIC AND LOCAL EX VIVO GENE THERAPY OF THE SKELETON - Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (PDGF) B, and wherein the multipotent stem cells express a sufficient amount of PDGFB to increase bone mass and strength or bone fracture healing. A lentiviral vector also is disclosed that includes a phosphoglycerate kinase-1 (PGK) promoter operably linked to a nucleic acid encoding PDGFB. | 2016-05-05 |
| 20160120945 | Thymic Regeneration - Methods for regenerating thymic tissues, e.g., for the treatment of subjects who have thymic insufficiency, i.e., whose thymic tissues are absent or atrophied due to illness, age, or injury, by administration of growth differentiation factor 11 (GDF11). | 2016-05-05 |
| 20160120946 | COMPOSITIONS COMPRISING GC-MACROPHAGE ACTIVATING FACTOR AND USES THEREOF - A pharmaceutical composition that includes stable Gc macrophage activating factor (GcMAF) or a biologically active variant or fragment thereof and at least one pharmaceutically acceptable excipient selected from the group consisting of a surfactant and a synthetic water-soluble polymer having surface activity. These compositions are storage stable and are used for treating a disease or disorder associated with macrophage activation. | 2016-05-05 |
| 20160120947 | METHODS AND COMPOSITIONS FOR MOBILIZING STEM CELLS - The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and/or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and/or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and/or progenitor cell transplantation. | 2016-05-05 |
| 20160120948 | IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) useful for improving hematopoietic recovery HSCT transplantation in a subject. In particular, the instant disclosure provide exemplary methods and compositions comprising IL-12 promoted hematopoiesis and increased the recovery of peripheral blood cells and survival in lethally irradiated mice as effectively as a BMCT, indicating that rHuIL-12 therapy can to increase HSC engraftment following HSCT. We identified IL-12Rβ2 expressing cells in irradiated mouse bone marrow which are potential targets of IL-12. Administration of rMuIL-12 increased the number of IL-12R□2 expressing Lin− cells in mouse bone marrow, indicating that bone marrow HSCs and niche cells are the direct target of rMuIL-12 and that hematopoiesis-promoting activity of rMuIL-12 is mediated by IL-12 receptors on HSCs. Finally, we show expression of IL-12β2 on human bone marrow lin− and CD34+ cells, indicating a potential role for IL-12 in human transplantation. | 2016-05-05 |
| 20160120949 | USES OF IL-12 IN HEMATOPOIETIC IMMUNOTHERAPY (HIT) - Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising interleukin 12 (IL-12) as a hematopoietic immunotherapy (HIT) useful for treating or preventing a cancer patient from chemotherapy-induced cytopenias necessitating a dose reduction and/or dose delay. following exposure of the patient to chemotherapeutic agents, the method comprising: administering a dose of therapeutically effective amount of a pharmaceutical composition comprising substantially isolated IL-12 to the subject, whereby cytopenias are reduced and leading to increases responses to the chemotherapy agent(s).diminished. | 2016-05-05 |
| 20160120950 | Pharmaceutical Formulations Comprising Incretin Mimetic Peptide and Aprotic Polar Solvent - The present disclosure is directed to stable pharmaceutical formulations and uses thereof. | 2016-05-05 |
| 20160120951 | ACYLATED GLUCAGON ANALOGUES - The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | 2016-05-05 |
| 20160120952 | THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 2016-05-05 |
| 20160120953 | Factor VIII Conjugates - The present invention relates to FVIII conjugated to heparosan (HEP) polymers, methods for the manufacture thereof and uses of such conjugates. The resultant conjugates may be used in the treatment or prevention of bleeding disorders such as haemophilia. | 2016-05-05 |
| 20160120954 | Pharmaceutical Composition Suitable for Treatment of Haemophilia - The present invention relates to pharmaceutical compositions suitable for treatment of haemophilia. | 2016-05-05 |
| 20160120955 | COMPOSITIONS COMPRISING COLLAGEN AND PRP FOR TISSUE REGENERATION - A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (PRP) and an inorganic salt. Methods of generating same and uses thereof are also disclosed. | 2016-05-05 |
| 20160120956 | COMPOSITION OF ERYTHROCYTES ENCAPSULATING PHENYLALANINE HYDROXYLASE AND THERAPEUTIC USE THEREOF - The present invention relates to Enzyme Replacement Therapy (ERT) based on phenylalanine hydroxylase (PAH) and compositions intended for this use. It concerns an erythrocyte encapsulating PAH, especially in suspension in a pharmaceutically acceptable carrier or vehicle, a pharmaceutical composition comprising erythrocytes encapsulating PAH in a pharmaceutically acceptable carrier or vehicle, and such a pharmaceutical composition for use in the treatment or prevention of phenylketonuria (PKU) and/or other diseases involving a too high level of phenylalanine; the treatment or prevention may be in combination with a Phe-restricted diet. The invention particularly relates to classic PKU, variant PKU and non-PKU hyperphenylalaninemia. | 2016-05-05 |
| 20160120957 | DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B. | 2016-05-05 |
| 20160120958 | MARKER FOR ACID SPHINGOMYELINASE DISORDERS AND USES THEREOF - The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy. | 2016-05-05 |
| 20160120959 | Use of Klotho Nucleic Acids or Proteins for Treatment of Diabetes and Diabetes-Related Conditions - In one embodiment, the inventive concepts include a method of treating a diabetic condition or a diabetes-related condition in a subject in need of such treatment by administering to the subject a therapeutically-effective amount of a vector comprising a nucleic acid which encodes a klotho protein or a therapeutically-effective portion of a klotho protein, wherein the klotho protein or therapeutically-effective portion of the klotho protein is expressed in vivo in pancreatic beta cells of the subject. In another embodiment, the inventive concepts include a method of treating a diabetic condition or a diabetes-related condition in a subject in need of such treatment by administering to the subject a therapeutically-effective amount of at least one of a klotho protein and a therapeutically-effective portion of the klotho protein. | 2016-05-05 |
| 20160120960 | ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM - A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease. | 2016-05-05 |
| 20160120961 | TREATMENT OF MERKEL CELL POLYOMAVIRUS INFECTION - The present disclosure provides novel compositions and methods for treating an infection of the skin resulting from an infection of a member of the | 2016-05-05 |
| 20160120962 | APOBEC3A AS AN ANTI-TUMOR AGENT - The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient. | 2016-05-05 |
| 20160120963 | BILE SALT HYDROLASE BSH1 FOR REGULATING WEIGHT GAIN, SERUM CHOLESTEROL LEVELS, AND LIVER TRIGLYCERIDES IN A MAMMAL; BACTERIA STRAINS EXPRESSING BSH1 VARIANTS - A non-therapeutic method of reducing weight gain, serum cholesterol levels, or liver triglyceride levels, in a non-obese mammal, comprises the step of administering to the gut of a mammal an effective amount of a bacteria expressing a BSH1 enzyme of SEQUENCE ID NO: 1, or a functional variant thereof; a BSH1 enzyme of SEQUENCE ID NO: 1, or a functional variant thereof for use as a medicament; isolated bacterial strains expressing functional variants of BSH1. | 2016-05-05 |
| 20160120964 | PROCESSES FOR PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE HAVING LIPASE ACTIVITY AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE - Processes are described for producing solid or semi-solid compositions, in particular solid oral compositions for pharmaceutical use, comprising treating an enzyme or enzyme-mixture with lipase-activity and a surfactant-component at defined process parameters. Said processes are suited for diminishing undesired biological contamination, e.g. viral contamination, of the said enzyme or enzyme-mixture while maintaining its desired biological activities, e.g. enzymatic activities. The process is suitable for industrial use. Also described are solid or semi-solid compositions comprising an enzyme or enzyme-mixture having lipase activity, a surfactant-component and a polymeric additive, optionally comprising further auxiliaries. Said compositions can preferably be obtained by the processes as described herein. Further described are pharmaceutical compositions comprising the solid or semi-solid compositions as described herein. | 2016-05-05 |
| 20160120965 | VACCINE PEPTIDE COMBINATIONS AGAINST CAT ALLERGY - The present invention relates to compositions comprising peptides for preventing or treating allergy to cats, and in particular to optimal combinations of peptides | 2016-05-05 |
| 20160120966 | BIOLOGICAL MARKERS USEFUL IN CANCER IMMUNOTHERAPY - Methods are disclosed that are based on the finding that serum and plasma levels of eotaxin, MIP1α, and CRP act as important biomarkers that are useful for determining the feasibility in instigating immunotherapeutic treatment of cancer when immunizing with the GV1001 peptide (EARPALLTSRLRFIPK; derived from human telomerase protein), optionally when combined with state of the art combination treatment with Gemcitabine and Capecitabine. In particular, the present invention provides methods for determining whether patients should be treated GV1001 and for determining whether instigated treatment should be continued. | 2016-05-05 |
| 20160120967 | MODIFIED ENDOTOXIC BACTERIA LIPOPOLYSACCHARIDE (VARIANTS), COMBINATION OF MODIFIED LIPOPOLYSACCHARIDES (VARIANTS) AND, CONTAINING SAME, A VACCINE (VARIANTS) AND A PHARMACEUTICAL COMPOSITION (VARIANTS) - For the first time individual (free from impurities of penta- and hexa-acetylated derivatives) di-, tri- and tetra-acetylated S-LPS of endotoxic bacteria and combinations thereof were obtained and their immunobiological, physical-chemical and chemical-pharmaceutical properties were studied. | 2016-05-05 |
| 20160120968 | Compositions and Methods for Immunizing Against C. Difficile - This disclosure relates to methods for eliciting an immune response against | 2016-05-05 |
| 20160120969 | COMBINATION VACCINE - The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides. | 2016-05-05 |
| 20160120970 | COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES - The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-γ, IL-I β, serum amyloid-A (SAA), IL-6 and/or β-defensin associated with infection or an immune response generally. | 2016-05-05 |
| 20160120971 | IMMUNOGENIC COMPOSITION COMPRISING NEISSERIA MENINGITIDIS MACROPHAGE INFECTIVITY POTENTIATOR PROTEIN AND METHODS FOR USING THEM - An immunogenic composition comprising the Nm-MIP protein or an immunogenic part thereof or an analogue thereof, wherein the composition is capable of eliciting an immune response when administered to a human or non-human animal, and uses thereof. A pharmaceutical composition or a vaccine composition comprising the Nm-MIP protein or an immunogenic part thereof or an analogue thereof. | 2016-05-05 |
| 20160120972 | INACTIVATED DENGUE VIRUS VACCINE WITH ALUMINIUM-FREE ADJUVANT - The present disclosure provides immunogenic compositions for the prevention and/or treatment of disease caused by dengue virus. | 2016-05-05 |
| 20160120973 | Attenuated Swine Influenza Vaccines and Methods of Making and Use Thereof - This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered | 2016-05-05 |
| 20160120974 | SEMI-LIVE RESPIRATORY SYNCYTIAL VIRUS VACCINE - The present invention relates to a semi-live respiratory syncytial virus (RSV) vaccine, which comprises a genome replication-deficient Sendai virus (SeV) vector expressing a chimeric RSV/SeV F protein. Furthermore, the present invention relates to a method for the production of the genome replication-deficient SeV vector of the present invention, and the use thereof in the treatment of RSV infections and RSV infection-related diseases. | 2016-05-05 |
| 20160120975 | FISH VACCINE - A composition comprising a translocation sequence derived from a fish pathogen and a heterologous payload coupled to the translocation sequence is provided. The composition is able to translocate across the plasma membrane of a eukaryotic cell, for example a fish cell, and thus stimulate an immune response. Accordingly, nucleic acids, vectors, host cells, compositions and vaccines based thereon are also provided. | 2016-05-05 |
| 20160120976 | COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA - The present invention concerns methods of treating relapsed/resistant non-Hodgkin's lymphoma using combination therapy with an anti-CD20 antibody or fragment and an anti-CD74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent. The combination is effective to treat indolent NHL that is resistant to or relapsed from at least one therapy for NHL, including but not limited to rituximab resistant NHL. The antibody combination may be administered to human subjects at specific dosages and dosing schedules, that are effective to treat the disease but do not induce a dose-limiting toxicity. | 2016-05-05 |
| 20160120977 | PROTEINS MODIFIED WITH (AMINO) MONOSACCHARIDE-BIOTIN ADDUCT - A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination. | 2016-05-05 |
| 20160120978 | TITANIUM NITRIDE PLASMONIC NANOPARTICLES FOR CLINICAL THERAPEUTIC APPLICATIONS - Disclosed herein are nanoparticle-based plasmonic solutions to therapeutic applications employing titanium nitride (TiN) and other non-stoichiometric compounds as the plasmonic material. Current solutions are suboptimal because they require complex shapes, large particle sizes, and a narrow range of sizes, in order to achieve plasmonic resonances in the biological window. The nanoparticles discloses herein provide plasmonic resonances occurring in the biological window even with small sizes, simple shapes, and better size dispersion restrictions. Local heating efficiencies of such nanoparticles outperform currently used Au and transition metal nanoparticles. The use of smaller particles with simpler shapes and better heating efficiencies allows better diffusion properties into tumor regions, larger penetration depth of light into the biological tissue, and the ability to use excitation light of less power. | 2016-05-05 |
| 20160120979 | METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT - A method applying a composition to a human or non-human individual or to an object or a surface area and a pharmaceutical composition with a regimen of administering it to a human or non-human individual is provided. The composition includes an active chemical component for killing of or retarding proliferation of target cells including pathogens, infected cells and cancer cells. The application of the composition and the regimen of administration of the composition are accompanied by at least one exposure to electromagnetic radiation in a range of wavelengths in which the active chemical component absorbs and which has a lower limit of 190 nm, thereby photo-activating the active component. | 2016-05-05 |
| 20160120980 | REGIONAL CANCER THERAPY - This invention relates to compositions and methods of treating cancers, and more particularly to regional delivery of cancer therapy compositions on surrounding internal tissues after surgery to remove or ablate cancer cells. The composition of the present invention can comprise an antineoplastic agent, such as, 5-Fluorouracil (“5-FU”) in an aqueous fluid, and a transcellular transport agent. An example of a composition of an embodiment of the present invention is 5-fluorouracil in an aqueous solution with polyethylene glycol and isopropanol. | 2016-05-05 |
| 20160120981 | HYALURONIC ACID STABILIZER - An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule. | 2016-05-05 |
| 20160120982 | VACCINE STABILIZER - Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: | 2016-05-05 |
| 20160120983 | PHARMACEUTICAL COMPOSITION WITH INCREASED SOLUBILITY BY USING SACCHARIN - The present invention provides a pharmaceutical composition including an ionic liquid composed of a triptan compound and saccharin. Since a triptan compound and saccharin form an ionic liquid to increase the solubility of the triptan compound in the present invention, it is possible to expect a rapid and high dissolution of the triptan compound when a pharmaceutical composition is prepared. In addition, large amounts of organic solvents and acidic solvents need not be used in order to dissolve the triptan compound. | 2016-05-05 |
| 20160120984 | SUGAR CONTAINING, AMPHIPHILIC COPOLYMERS - Disclosed herein are polymers made from at least one monomer of formulae (I), (II), (III), and (IV), in combination with a monomer of formula (V) that may be used in pharmaceutical formulations. These polymers comprise a hydrocarbon backbone and are made from monomers that contain at least one carbon-carbon double bond. Methods of making these polymers are also disclosed. | 2016-05-05 |
| 20160120985 | MOLECULAR ASSEMBLY USING AMPHIPATHIC BLOCK POLYMER, AND SUBSTANCE-CONVEYANCE CARRIER USING SAME - Provided is a molecular assembly having any nano-sized particle diameter depending on its intended use and application, in various fields such as pharmaceutical drugs, agricultural chemicals, cosmetics, food products, and electronics. Furthermore, provided is a nano-carrier for delivering various substances using the molecular assembly having any nano-sized particle diameter. A molecular assembly comprising: an amphiphilic block polymer A1 comprising a hydrophilic block having a sarcosine unit and a hydrophobic block having a lactic acid unit; and an amorphous hydrophobic polymer A2 having an aliphatic hydroxy acid unit, wherein a number of aliphatic hydroxy acid units contained in the amorphous hydrophobic polymer A2 exceeds twice a number of lactic acid units contained in the hydrophobic block of the amphiphilic block polymer A1. | 2016-05-05 |
| 20160120986 | DELIVERY SYSTEMS - Disclosed herein are delivery systems including coated and uncoated yarns, yarn precursors, threads, fibers, and other substrates for the constant or near-constant release of active compounds, as well as methods for manufacturing such delivery systems. The yarns, yarn precursors, threads, fibers, and other substrates can include a cross-linked hydrophobic elastomer and an active compound. One or more coatings that are impermeable or substantially impermeable to the active compound may partially or fully occlude the yarn or substrate to control release rates of the active compound. The delivery systems may be used in a variety of applications, including the making of articles of clothing, textiles, and fabrics, and may be used in methods of treating various conditions and diseases. | 2016-05-05 |
| 20160120987 | CHEMICAL STRUCTURES FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS - The present invention provides a method for selective delivery of a therapeutic or diagnostic agent to a targeted organ or tissue by implanting a biocompatible solid support in the patient being linked to a first binding agent, and administering a second binding agent to the patient linked to the therapeutic or diagnostic agent, such that the therapeutic or diagnostic agent accumulates at the targeted organ or tissue. | 2016-05-05 |
| 20160120988 | PAZOPANIB FORMULATION - A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension. | 2016-05-05 |
| 20160120989 | COPROCESSED SILICA COATED POLYMER COMPOSITION - An excipient composition having good bulk density and improved flow characteristics is provided. The present invention particularly provides a coprocessed excipient composition and a method of producing the same. The coprocessed excipient comprises cellulose derived polymer and a deagglomerated coprocessing agent. The coprocessing agent is fumed silica, colloidal silica or silicon dioxide. The coprocessed excipient is prepared in a continuous process and has excellent compactability and improved flow property as measured by Johanson flow rate number increase from 1.1 to 5.0 fold, is characterized by a Brookfield cohesion factor of less than 0.2 kPa and a bulk density of at least 0.249 g/ml. | 2016-05-05 |
| 20160120990 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A HYDROXYALKYL METHYLCELLULOSE - A composition designed for application to a mucosa comprises a tonicity-adjusting agent, a hydroxyalkyl methylcellulose and a liquid diluent, wherein the hydroxyalkyl methylcellulose has a DS of from 1.6 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, and at least 55 weight percent of the liquid diluent is water. When the composition comprises additionally a physiologically active agent, the composition may be used for transmucosal administration of the physiologically active agent to an individual. | 2016-05-05 |
| 20160120991 | SELF-ASSOCIATING MICROPARTICLES AND NANOPARTICLES CONSISTING OF PROTEINS - Microparticles and nanoparticles of hydrophobized proteins and an alpha-cyclodextrin, obtained by auto-association in an aqueous medium, the hydrophobized protein being obtained by grafting of alkyl chains coming from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulation of active substances of interest, in particular in the pharmaceutical field, and the vectorization thereof for therapeutic purposes. | 2016-05-05 |
| 20160120992 | COAGULATION FACTOR VII POLYPEPTIDES - The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment. | 2016-05-05 |
| 20160120993 | Activated Sialic Acid Derivatives For Protein Derivatisation And Conjugation - Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems. | 2016-05-05 |
| 20160120994 | BLOOD COAGULATION PROTEIN CONJUGATES - The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH | 2016-05-05 |
| 20160120995 | CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF - Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases, dermatitis and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis. | 2016-05-05 |
| 20160120996 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES - A novel delivery system for drugs, and especially macromolecules such as proteins or oligonucleotides through biological membranes is provided, and specifically delivery of siRNA. The delivery system comprises conjugation of the macromolecule drug to a moiety that enables effective passage through the membranes. Respectively, novel compounds and pharmaceutical compositions are provided, utilizing said delivery system. In one aspect of the invention, the compounds may be utilized in medical practice, for example, in delivery of siRNA or antisense oligonucleotides across biological membranes for the treatment of medical disorders. | 2016-05-05 |
| 20160120997 | Modified Glycoproteins Having Circulating Half-Lives - Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins. | 2016-05-05 |
| 20160120998 | Cell-Penetrating Drug Carrier and the Application Thereof - This invention is about a cell-penetrating drug carrier and the application thereof. The mentioned cell-penetrating drug carrier can approach the target cell through using a proper recognizable sequence, so that the cell-penetrating drug carrier can be used to specifically delivery wanted drug to target cell. Through carrying wanted drug into the cytoplasm of the target cell by cell-penetrating peptide, the drug accumulation volume in the target cell can be efficiently increased. Preferably, through using proper bioinert polymer, the cell-penetrating peptide and the recognizable sequence can be kept from been digested before approaching the target cell. | 2016-05-05 |
